BLA 761166 · Pharmaessentia Corp
Besremi
Ropeginterferon Alfa-2b-Njft · Subcutaneous · Interferon alfa-2b
NovelOrphanCDER novel approval, Nov 12, 2021: To treat polycythemia vera, a blood disease that causes the overproduction of red blood cells
Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Nov 12, 2021
Approved uses
2
Original approval plus efficacy supplements
Registered trials
31
11 Phase 3, 9 recruiting
FAERS reports
1,859
429 serious, 31 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF SERIOUS DISORDERS Risk of Serious Disorders: Interferon alfa products may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping therapy [see Warnings and Precautions ( 5.1 , 5,2 , 5.3 , 5.4 ) and Adverse Reactions ( 6.1 )] . WARNING: RISK OF SERIOUS DISORDERS See full prescribing information for complete boxed warning. Risk of Serious Disorders: Interferon alfa products may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor closely and withdraw therapy with persistently severe or...
What it is approved for
From the label in effect Aug 25, 2026.
BESREMi is an interferon alfa-2b indicated for: • The treatment of adults with essential thrombocythemia. ( 1.1 ) • The treatment of adults with polycythemia vera. ( 1.2 ) 1.1 Essential Thrombocythemia BESREMi is indicated for the treatment of adults with essential thrombocythemia. 1.2 Polycythemia Vera BESREMi is indicated for the treatment of adults with polycythemia vera.
Mechanism: Interferon alfa belongs to the class of type I interferons, which exhibit their cellular effects in polycythemia vera and essential thrombocythemia in the bone marrow by binding to a transmembrane receptor termed interferon alfa receptor (IFNAR). Binding to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) and activator of transcription (STAT) proteins. Nuclear translocation of STAT proteins controls distinct gene-expression programs and exhibits various cellular effects. The actions involved in...
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 28, 2026 Supplement 13 · Efficacy OrphanLetterLabelMedication Guide
- Nov 12, 2021 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
1 products under this application
- BESREMI · ROPEGINTERFERON ALFA-2B-NJFT 500 MCG/ML · INJECTABLE, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ropeginterferon Alfa-2b" as an intervention, any sponsor and status, largest first.
- A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential ThrombocythemiaPivotal-lookingRecruiting
Incyte CorporationIncyte (INCY)
NCT07623200 · 426 participants (planned) · Start Sep 8, 2026 · Primary completion Jun 15, 2029
Drug: INCA033989; Best Available Treatment · For: Essential Thrombocythemia
Sites: Birmingham, Alabama; Gilbert, Arizona; Duarte, California · 196 sites in all
- A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07722611 · 380 participants (planned) · Start Oct 29, 2026 · Primary completion Jun 25, 2032
Drug: Bomedemstat; Ruxolitinib and 1 more · For: Polycythemia Vera
Sites: Newark, Delaware; Columbia, Maryland; Eugene, Oregon · 8 sites in all
- Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 InfectionPivotal-lookingCompleted
PharmaEssentiaIndustry
NCT04382937 · 222 participants · Start Jan 12, 2016 · Primary completion Jul 15, 2020
Drug: P1101 + Ribavirin; PEG-Intron + Ribavirin · For: Chronic Hepatitis C Virus Infection
Sites: Beijing, China; Gansu, China; Harbin, China · 39 sites in all
- Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or IntolerancePivotal-lookingActive, not recruiting
PharmaEssentiaIndustry
NCT04285086 · 174 participants · Start Aug 25, 2020 · Primary completion Nov 12, 2024
Drug: Ropeginterferon alfa-2b; Anagrelide · For: Essential Thrombocythemia
Sites: Scottsdale, Arizona; St Louis, Missouri; Houston, Texas · 67 sites in all
- P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 RiskPivotal-lookingActive, not recruiting
PharmaEssentiaIndustry
NCT06468033 · 160 participants · Start Jul 18, 2025 · Primary completion Nov 18, 2027
Drug: Ropeginterferon alfa-2b · For: Primary Myelofibrosis; Myeloproliferative Neoplasm
Sites: Los Angeles, California; Washington D.C., District of Columbia; Kansas City, Kansas · 73 sites in all
- Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.Pivotal-lookingCompleted
National Taiwan University HospitalAcademic, hospital or other
NCT05770466 · 134 participants · Start Apr 1, 2022 · Primary completion Dec 21, 2022
Drug: P1101 (Ropeginterferon alfa-2b) · For: COVID-19
Sites: Taipei, Taiwan
- A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia PatientsPivotal-lookingActive, not recruiting
AOP Orphan Pharmaceuticals AGIndustry
NCT06514807 · 117 participants (planned) · Start Dec 4, 2023 · Primary completion Mar 15, 2028
Drug: Ropeginterferon alfa-2b (BESREMi®) · For: Essential Thrombocythaemia
Sites: Graz, Austria; Innsbruck, Austria; Linz, Austria · 36 sites in all
- A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PVPivotal-lookingActive, not recruiting
PharmaEssentiaIndustry
NCT05481151 · 111 participants · Start Oct 26, 2022 · Primary completion Jun 30, 2025
Drug: P1101 (Ropeginterferon alfa-2b-njft); Ropeginterferon alfa-2b-njft (P1101) · For: Polycythemia Vera
Sites: Jacksonville, Florida; Fort Wayne, Indiana; Westwood, Kansas · 23 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue355
- off label use304
- pruritus177
- headache157
- product dose omission issue118
- influenza like illness111
- nausea110
- inappropriate schedule of product administration107
- diarrhoea104
- pain104
- arthralgia101
- haematocrit increased93
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 382 |
| 2023 | 774 |
| 2024 | 217 |
| 2025 | 189 |
| 2026 | 292 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Besremi (Ropeginterferon Alfa-2b-Njft)
2024 spending
$81.2M
Beneficiaries
704
5,334 claims
Per beneficiary
$115,338
$8,230.93 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $20,049,428 |
| 2023 | $39,923,392 |
| 2024 | $81,198,106 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Gisslinger H, Klade C, Georgiev P, et al. · Lancet Haematol 2020 · Clinical Trial, Phase III, Comparative Study
- Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.
Barbui T, Vannucchi AM, De Stefano V, et al. · NEJM Evid 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.
Mesa R, Gill H, Zhang L, et al. · Lancet Haematol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
Barbui T, Vannucchi AM, De Stefano V, et al. · Lancet Haematol 2021 · Clinical Trial, Phase II, Multicenter Study
- Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera.
Kirito K, Sugimoto Y, Gotoh A, et al. · Int J Hematol 2024 · Clinical Trial, Phase II, Multicenter Study
- Ropeginterferon dose-escalation strategies in polycythemia vera: a systematic review and meta-analysis.
Yoon SY, Park S, Jeong SY, et al. · BMC Cancer 2026 · Systematic Review, Meta-Analysis
Sponsor: Pharmaessentia Corp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.